Omberacetam (brand name Noopept, developmental code GVS-111) is a synthetic dipeptide nootropic compound developed by the Zakusov State Institute of Pharmacology in Russia. Despite being structurally related to the racetam family — it shares the pyrrolidone nucleus characteristic of racetams — omberacetam is technically a dipeptide (N-phenylacetyl-L-prolylglycine ethyl ester) rather than a true racetam. It is substantially more potent than piracetam on a weight-for-weight basis: typical effective doses are 10–30 mg, compared to 1,600–4,800 mg for piracetam. This dramatically lower effective dose has made it popular in the nootropic community as an efficient, economical alternative.
Omberacetam exerts its effects through multiple mechanisms. It modulates AMPA receptor function (ampakine-like activity), stimulates the expression of nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) in the hippocampus, and enhances alpha/beta oscillatory activity in electroencephalographic recordings. The neurotrophic effects — particularly the upregulation of NGF and BDNF — distinguish omberacetam from simpler racetams and suggest a potential neuroprotective and neuroplasticity-enhancing mechanism beyond immediate receptor modulation.
In Russia, omberacetam has been approved as a prescription drug for the treatment of mild cognitive impairment associated with organic causes, and research was published in Russian medical literature throughout the 1990s and 2000s. Its popularization in Western nootropic communities in the 2010s occurred primarily through online forums and communities where users described effects including improved verbal articulation, enhanced recall, visual clarity, and a mild stimulant edge. Tolerance develops with continuous use, and its importance of cycling is strongly emphasized by experienced users; cross-tolerance with other racetam nootropics has also been noted.